The earnings call conveyed a predominantly positive outlook, driven by the increased financial consideration from the FibroGen China sale, which extends the company's cash runway significantly. The initiation of new clinical trials and positive regulatory feedback further support this sentiment. However, the limited revenue growth and ongoing net losses were noted as areas of concern.

Company Guidance

During the FibroGen Second Quarter 2025 Earnings Conference Call, the company provided updated financial guidance and strategic priorities. FibroGen announced an expected total consideration of approximately $210 million from the sale of FibroGen China to AstraZeneca, reflecting a $50 million increase from initial guidance. This transaction is anticipated to simplify operations, enable the payoff of a term loan with Morgan Stanley Tactical Value, and extend the company's cash runway into 2028. Additionally, the company remains focused on advancing FG-3246, an antibody drug conjugate for metastatic castration-resistant prostate cancer, with a Phase II monotherapy trial set to begin in the third quarter of 2025. For roxadustat, FibroGen plans to submit a Phase III trial protocol to the FDA in the fourth quarter of 2025 for treating anemia associated with lower-risk myelodysplastic syndromes. Financially, FibroGen reported total revenues of $1.3 million for the second quarter of 2025 and updated its full-year revenue guidance to be between $6 million and $8 million, with total operating costs and expenses expected to range from $65 million to $75 million.

Increased Total Consideration for FibroGen China Sale

The total consideration for the sale of FibroGen China to AstraZeneca is now expected to be approximately $210 million, a $50 million increase from initial guidance due to greater-than-expected net cash in China at closing.

Extended Cash Runway

The increased cash from the FibroGen China sale further extends the company's cash runway into 2028.

Phase II Monotherapy Trial Initiation

FibroGen is on track to begin a Phase II monotherapy trial of FG-3246 and FG-3180 in the third quarter of 2025.

Positive Regulatory Feedback

FibroGen had a positive Type-C meeting with the FDA and alignment on key elements for a pivotal Phase III trial for roxadustat.

Significant Reduction in Operating Costs

Total operating costs and expenses for Q2 2025 were $13.4 million, a 72% decrease from the second quarter of 2024.

FibroGen (FGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FGEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-4.00 / -	-4.25	―	―	―
Aug 11, 2025	2025 (Q2)	-2.30 / -1.88	-4	53.00% (+2.12)
May 12, 2025	2025 (Q1)	0.75 / 1.25	-8.25	115.15% (+9.50)
Mar 17, 2025	2024 (Q4)	-3.50 / 4.50	-14.25	131.58% (+18.75)
Nov 12, 2024	2024 (Q3)	-7.66 / -4.25	-16.25	73.85% (+12.00)
Aug 06, 2024	2024 (Q2)	-8.00 / -4.00	-22.5	82.22% (+18.50)
May 06, 2024	2024 (Q1)	-10.45 / -8.25	-20.25	59.26% (+12.00)
Feb 26, 2024	2023 (Q4)	-10.63 / -14.25	-17.5	18.57% (+3.25)
Nov 06, 2023	2023 (Q3)	-17.03 / -16.25	-24.5	33.67% (+8.25)
Aug 07, 2023	2023 (Q2)	-17.60 / -22.50	-19.5	-15.38% (-3.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FGEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$8.37	$9.25	+10.51%
May 12, 2025	$7.64	$7.48	-2.09%
Mar 17, 2025	$11.12	$8.70	-21.76%
Nov 12, 2024	$9.66	$8.30	-14.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does FibroGen (FGEN) report earnings?

FibroGen (FGEN) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is FibroGen (FGEN) earnings time?

FibroGen (FGEN) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FGEN EPS forecast?

FGEN EPS forecast for the fiscal quarter 2025 (Q3) is -4.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing